NEW YORK, April 9, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Gilead Sciences, Inc. (NASDAQ: GILD), Agios Pharmaceuticals, Inc.
(NASDAQ: AGIO), Mindray Medical International Limited (NYSE: MR),
BG Medicine, Inc. (NASDAQ: BGMD), and Ultragenyx Pharmaceutical,
Inc. (NASDAQ: RARE). Private wealth members receive these notes
ahead of publication. To reserve complementary membership, limited
openings are available at:
http://www.AnalystsReview.com/register
--
Gilead Sciences, Inc. Analyst Notes
On April 2, 2014, Gilead Sciences,
Inc. (Gilead Sciences) announced topline results from a Phase 3
clinical trial in Japan evaluating
the once-daily nucleotide analog polymerase inhibitor sofosbuvir in
combination with ribavirin (RBV) for the treatment of genotype 2
chronic hepatitis C virus (HCV) infection. According to the
results, the study met its primary efficacy endpoint of superiority
compared to a predefined historical control sustained virologic
response (SVR) rate. "This study confirms the high efficacy of
all-oral therapy with sofosbuvir among genotype 2 hepatitis C
patients in Japan, regardless of
whether they are treatment experienced or new to treatment," said
Norbert Bischofberger, PhD,
Executive Vice President of Research and Development and Chief
Scientific Officer at Gilead Sciences. The full analyst notes on
Gilead Sciences, Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/04092014/GILD/report.pdf
--
Agios Pharmaceuticals, Inc. Analyst Notes
On March 24, 2014, Agios
Pharmaceuticals, Inc. (Agios) announced dose administration for the
first patient in a Phase 1 study of AG-120 in patients with
advanced solid tumors with an isocitrate dehydrogenase-1 (IGHI1)
mutation. The Company informed that this is the second Phase 1
study of AG-120. "We are pleased to have rapidly initiated two
studies evaluating AG-120 in a broad range of solid tumors and
hematologic cancers with IDH1 mutations," said David Schenkein, M.D., CEO of Agios. "Both of
these studies employ a precision medicine approach that will
evaluate AG-120 among diagnostically identified patient
populations, with a goal of generating valuable early data about
this cancer metabolism development program. We believe the approach
of targeting IDH mutations in cancer holds great promise for
patients." The full analyst notes on Agios Pharmaceuticals, Inc.
are available to download free of charge at:
http://www.AnalystsReview.com/04092014/AGIO/report.pdf
--
Mindray Medical International Limited Analyst
Notes
On April 3, 2014, Mindray Medical
International Limited (Mindray) announced that it intends to
exhibit more than 70 of its products at the 71st China
International Medical Equipment Fair (CMEF) in Shenzhen, China. The event will be held on
April 17-20, 2014. Mindray informed
that it will showcase the latest products from its three primary
business segments - patient monitoring and life support, in-vitro
diagnostics, and medical imaging systems. In addition, the Company
also intends to display some products from recently acquired
businesses. The full analyst notes on Mindray Medical International
Limited are available to download free of charge at:
http://www.AnalystsReview.com/04092014/MR/report.pdf
--
BG Medicine, Inc. Analyst Notes
On Mach 25, 2014, BG Medicine, Inc. (BG Medicine) announced the
publication of results of an analysis of aggregated data from three
large, multicentre clinical research trials in the US and
Europe, in the American Heart
Journal. According to the published results, the trials included a
total of 902 heart failure patients and demonstrated that
elevations of galectin-3 levels in blood, as measured using the BGM
Galectin-3 Test, were significantly predictive of rehospitalisation
for heart failure as early within the first 30 days following
discharge from an initial hospital stay. "We believe that this
analysis of data from three significant clinical research trials
further affirms the previously reported utility of galectin-3
testing as an aid in assessing the prognosis of patients with heart
failure when used in conjunction with clinical evaluation," said
Dr. Paul R. Sohmer, President and
CEO of BG Medicine. The full analyst notes on BG Medicine, Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/04092014/BGMD/report.pdf
--
Ultragenyx Pharmaceutical, Inc. Analyst Notes
On March 27, 2014, Ultragenyx
Pharmaceutical, Inc. (Ultragenyx) announced the presentation of
preliminary data from the Phase 1/2 study of recombinant human
beta-glucuronidase (rhGUS, UX003), an investigational therapy for
the treatment of mucopolysaccharidosis (MPS 7, sly syndrome).
According to the preliminary results from three patients who have
been administered 2 mg/kg of rhGUS every other week for two, six,
and 12 weeks, there was a decline in urinary glycosaminoglycan
(GAG) excretion beginning at two weeks of treatment of
approximately 30-50%, indicating evident clearance of lysosomal
storage. Further, the results show that at the 12 weeks of
assessment of the first patient, absolute liver size was reduced by
approximately 11%, representing a 46% decrease in the excess liver
size above normal for age and gender. The full analyst notes on
Ultragenyx Pharmaceutical, Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/04092014/RARE/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review